INTRODUCTION
Cancer is increasing worldwide, and residents of low-and middle-income countries present a greater morbidity and mortality. [1] Sometimes, cancer manifests as a paraneoplastic syndrome that challenges its correct diagnosis; this is the case of Trousseau's syndrome (TSx): Deep-vein thrombosis (DVT) in patients with an underlying malignancy. [2, 3] Furthermore, TSx may be the herald of occult cancer and it may be its first sign. [4] Some studies have found that occult cancer occurs in nearly 10% of DVT cases. [4] In Mexico, there is only one retrospective study, in a service of oncology, about DVT in patients with a previous diagnosis of cancer. [5] Hence, in Mexico, there are no data available about the frequency of occult cancers in patients with primary DVT trauma, pregnancy, coagulopathies (lupus, protein C or S deficiency); platelets disorders, long-lasting immobilization during the past 6 months, estrogen use, autoimmune diseases, and childbirth were excluded from the study.
Procedures
Initially, all cases with primary DVT were assessed with a full clinical history and a thorough physical examination. Their evaluation included D-dimer, complete blood count, creatinine, activated partial thromboplastin time, transaminases, gamma-glutamyl transpeptidase, and alkaline phosphatase. Besides, duplex venous ultrasonography of the affected extremity, abdominal-pelvic ultrasound, and chest X-rays were done.
According to individual clinical data, the evaluation was extended to thoracic-abdominopelvic computed tomography (CT scan), CT scan of head-neck-thorax, transabdominal prostate ultrasound, mammography, Pap smear, neck ultrasound, gastroscopy, colonoscopy or sigmoidoscopy, and biopsies whenever possible. Furthermore, tumor markers including carcinoembryonic antigen, α-fetoprotein, CA-125, CA-15.3, and total specific prostate antigen were obtained, if necessary. This approach was a modification to the SOMIT study. [6] The Department of Vascular Surgery follows up the patients with DVT during 6 months after the diagnosis and no signs of cancer, according to standard protocols.
With an objective diagnosis of cancer achieved, the treatment to patients with DVT was with low-molecular-weight heparin. Then, the patients were sent to the oncology department, and treatment was performed according to standard protocols.
Statistical methods
All values are expressed in absolute numbers and percentages; the descriptive statistic was used.
RESULTS
There were totally 182 patients with primary DVT: 135 (74%) females and 47 (26%) males, with an average age of 63 years. Of these patients, 30 (16.5%) had occult cancer; 13 (43%) males and 17 (57%) females with an average age of 61 years.
In males, prostate cancer prevailed (6/13, 46%) followed by colorectal tumors. Meanwhile, in females, the pelvic gynecologic malignant neoplasms (cervix, uterus, and ovarian cancers, 7/17, 41%) predominated, tracked by stomach cancer (4/17, 23%) [ Table 1 ].
DISCUSSION
This study establishes that occult cancer occurs in 16.5% of patients with primary DVT at a general hospital in Mexico City. There are no similar studies in Mexico and Latin America to compare. From seven studies of primary DVT and occult cancer found in different repositories (PubMed, Google academic, EBSCO, Scopus, and Lilacs), only two, one prospective and other retrospective, are in accordance with our findings of a major prevalence of women and mean age [ Table 2 ]. [4, 6] Besides, three more studies agree with occult prostate cancer as a main associated malignant neoplasm with primary DVT. [6] [7] [8] And only one, with a greater frequency of gynecologic tumors, associated with DVT. [9] In a contrary sense to our information, five studies find that the DVT with occult cancer affected men more frequently than women [ Table 2 ]. [6] [7] [8] [9] [10] Moreover, four investigations find different main cancers affecting its evaluated patients. These circumstances could be explained according to the well-known geographical differences in cancer risk factors. [1] We are well aware of the limitations of our study. It was a study conducted only in one hospital, and it is reasonable that our circumstances are not applicable to other clinical settings; we only evaluated DVT in lower extremities; furthermore, we did not evaluate the impact of cancer stage on patients' survival. However, our research has some advantages. The analysis of 182 patients with DVT, in a 3-year study of a single second-level hospital, is a good sample; only to have a perspective, in a 1-year multi-institutional study of all Argentina, 181 patients were found with venous thromboembolism. [11] If our results are verified, it would determine to change how we should evaluate the patients with DVT in our country. Furthermore, there is a great need for further studies regarding how extensive the screening for occult cancer should be, and its costs. In addition, it is critical to establish the malignant neoplasm stage when it is noticed, and whether a prompt diagnosis could impact on patients' survival, due to conflicting data in a recent bibliography. [6, 9] Our results drive us to some advices. Considering that one in six patients (16.5%) with primary DVT may have occult cancer in our country, it is rational to assess this option in all cases; in addition, in men, the digital prostatic rectal examination is essential; and in women, the pelvic gynecologic examination is crucial. In literature, there is no agreement as to how extensive screening for occult cancer should be in primary DVT patients with no apparent risk factors. In this sense, we recommend using a modification of SOMIT's study protocol, to detect more patients affected with neck cancers. In addition, from an economic point of view, it is advisable first to use an elementary approach and, only if needed, later to employ complex and expensive studies.
CONCLUSION
Our results suggest that in Mexican patients with primary DVT, occult cancer is frequent. Our results warrant additional projects.
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